Heat Crisis in Cyprus, Stroke Risk from Drugs, and Sleep's Role in Aging

Five stories from Tuesday, 25 August 2026 and the preceding 72 hours.

Tuesday, 25 August: Cyprus Issues Third Straight Heat Warning as Hospitals Fill

Cyprus's Meteorological Service issued a yellow heat warning for the third consecutive day on Tuesday, with inland temperatures expected to reach or exceed 41°C. Accident and emergency departments at public hospitals across the island — including in coastal areas where tourists and locals are crowding beaches — have reported a marked increase in patients presenting with heat exhaustion, dehydration, and gastroenteritis. Hospitals have added reserve beds and called staff back from summer leave to keep critical units fully staffed. The Ministry of Health has urged residents, especially older adults, young children, and outdoor workers, to stay indoors between 11:00 and 17:00, drink water consistently throughout the day, and check on neighbours who live alone.

Cyprus is among the Mediterranean countries most exposed to prolonged heatwaves under current climate trajectories, according to the WHO. Emergency admissions are being compounded by staff shortages from summer leave, and health authorities are monitoring the situation closely. People with chronic cardiovascular or respiratory conditions face the greatest additional risk during sustained heat events of this kind.

Monday, 24 August: Common Medications May Reshape the Gut Microbiome for Years After the Last Dose

A study of more than 2,500 people, published Monday in mSystems, the journal of the American Society for Microbiology, found that nearly half of 186 tested medications produced detectable changes in the gut microbiome — and that for many drugs, those changes persisted for years after the patient had stopped taking them. The effect was strongest for antibiotics, long known to disturb gut bacteria, but the analysis also documented lasting changes linked to antidepressants (particularly SSRIs), beta-blockers, proton-pump inhibitors, and benzodiazepines. For some medications the effect was additive: repeated use compounded the disruption.

Among the mechanisms identified, beta-blockers and SSRI antidepressants were found to alter bacterial functions involved in vitamin biosynthesis, which may have broader downstream effects on host health. The researchers note that the findings do not establish clinical harm from any individual medication — many of the drugs involved confer clear therapeutic benefit — but the results suggest that a person's complete prescription history, including treatments stopped years earlier, may partly explain the microbial differences researchers observe between individuals today. The study was covered by ScienceDaily and is the first to examine such a breadth of drug classes in a single longitudinal analysis.

Sunday–Monday, 23–24 August: Nature Study Maps the Sleep Sweet Spot Across 17 Organs

A landmark study published in Nature — drawing wide attention this week after press briefings at King's College London and Columbia University's Irving Medical Center — analysed data from approximately 500,000 adults in the UK Biobank and used machine learning to track 23 biological aging clocks spanning 17 organ systems, including the brain, heart, lungs, liver, and immune system.

The central finding was a U-shaped curve: both sleeping fewer than six hours and more than eight hours per night were associated with faster biological aging across nearly every organ examined. The least aging occurred in people reporting between 6.4 and 7.8 hours of sleep per day — with the optimal point for brain aging specifically falling at around 7.8 hours for women and 7.7 hours for men. Organs age at different rates and are not equally sensitive to sleep patterns, the researchers note: the immune system, brain, and cardiovascular system showed the sharpest association with sleep duration.

The study is observational: sleeping outside the sweet spot may reflect underlying illness or poor health rather than being solely a cause of accelerated aging. What makes this work notable is its scope — 17 organ systems, a half-million participants, and 23 independent aging clocks — giving it statistical depth that smaller previous studies on sleep and health lacked. The research also identified a direct association between sleep duration and late-life depression, a connection that may reflect shared inflammatory or circadian pathways.

Friday, 22 August: Cannabis Raises Stroke Risk by 37%; Cocaine and Amphetamines Nearly Double It

Researchers at the University of Cambridge pooled data from 32 studies involving more than 100 million people and found that three widely used recreational drugs — cannabis, cocaine, and amphetamines — substantially raise the risk of stroke, including among younger adults. Cannabis users had a 37% higher stroke risk than non-users in the analysis; the figure climbed to 96% for cocaine and 122% for amphetamines. Opioid use did not reach statistical significance for stroke risk in this dataset. The paper was published in the International Journal of Stroke.

The Cambridge team conclude that it is the pharmacological properties of these drugs — not simply shared lifestyle factors among users — that drive the elevated risk. For stroke physicians, the finding reinforces existing clinical guidance: when a young or middle-aged adult presents with an unexplained cerebrovascular event, recreational substance use should be part of the standard history-taking. The authors acknowledge the inherent limits of pooled epidemiological data and note that individual-level causation cannot be definitively established, but the consistency of the association across more than 100 million participants across 32 studies is difficult to dismiss.

Thursday, 21 August: UC Berkeley Compound Raises Energy Expenditure 18% in Mice — A New Angle for Obesity Research

Researchers at UC Berkeley published results in Science Advances describing TOFA (5-tetradecyloxy-2-furoic acid), a decades-old compound that may point toward a mechanistically distinct approach to treating obesity. Where GLP-1 drugs such as semaglutide work primarily by suppressing appetite and slowing gastric emptying, TOFA acts by blocking the production of lipids while simultaneously activating genes that prompt cells to burn fat and generate energy — an 18% increase in energy expenditure in the mouse models studied. Animals lost body fat without significant muscle loss and showed improvements in blood sugar, triglycerides, and markers of fatty liver disease. When combined with a GLP-1 drug, results were stronger than either agent alone.

These are preclinical findings in mice only. TOFA has not entered human clinical trials, and whether the compound's mechanism, efficacy, or safety profile would translate to humans remains unknown. The researchers present this work as a proof-of-concept for a complementary treatment strategy — targeting energy output rather than caloric intake — that could one day sit alongside existing therapies. Independent replication and eventual human trial data will be necessary before any clinical conclusion can be drawn. The study adds to a growing body of research seeking approaches to obesity that do not rely solely on appetite suppression.

---

The stories above are journalistic summaries for informational purposes only and do not constitute medical advice. Readers should consult a qualified clinician before making any change to treatment, medication, or health behaviour.